The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARTL | -80.5% | -99.38% | -63.76% | -100% |
| S&P | +17.78% | +74.31% | +11.75% | +164% |
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
No news articles found for Artelo Biosciences.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $7.39M | -29.2% |
| Market Cap / Employee | $1.06M | 0.0% |
| Employees | 7 | 16.7% |
| Net Income | -$4,166.00K | -10.3% |
| EBITDA | -$2,786.00K | 26.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $600.00K | -74.3% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $29.00K | -58.0% |
| Short Term Debt | $649.00K | 1754.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -343.49% | -232.7% |
| Return On Invested Capital | -155.59% | -90.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,919.44K | -22.1% |
| Operating Free Cash Flow | -$2,919.44K | -22.1% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 13.21 | 200.33 | -6.90 | -8.99 | -346.28% |
| Price to Tangible Book Value | 63.17 | -94.17 | -2.82 | -2.13 | -114.95% |
| Enterprise Value to EBITDA | -0.93 | -2.04 | -0.92 | -0.91 | 189.84% |
| Return on Equity | -190.7% | -356.5% | -436.1% | -1625.1% | 1108.08% |
| Total Debt | $95.00K | $878.00K | $954.00K | $678.00K | 551.92% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
